Tandem Diabetes Care Inc (TNDM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tandem Diabetes Care Inc (TNDM) has a cash flow conversion efficiency ratio of -0.181x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-23.58 Million) by net assets ($130.39 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see TNDM market cap overview for the company's overall valuation and market capitalisation.
Tandem Diabetes Care Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Tandem Diabetes Care Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Tandem Diabetes Care Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tandem Diabetes Care Inc ranked by their cash flow conversion efficiency. Explore Tandem Diabetes Care Inc (TNDM) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hotel101 Global Holdings Corp. Class A Ordinary Shares
NASDAQ:HBNB
|
N/A |
|
HBM HLDGS LTD DL-000025
F:6XY
|
N/A |
|
Aurisco Pharmaceutical Co Ltd
SHG:605116
|
N/A |
|
Streamax Technology Co Ltd
SHE:002970
|
0.049x |
|
Talant Optronics (Suzhou) Co. Ltd.
SHE:301045
|
N/A |
|
Tamboran Resources Corporation
NYSE:TBN
|
-0.032x |
|
Suzhou Shijia Science & Technology Inc
SHE:002796
|
-0.031x |
|
Hemab Therapeutics Holdings, Inc. Common Stock
NASDAQ:COAG
|
N/A |
Annual Cash Flow Conversion Efficiency for Tandem Diabetes Care Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Tandem Diabetes Care Inc from 2011 to 2025. View TNDM share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $155.17 Million | $-9.72 Million | -0.063x | -168.04% |
| 2024-12-31 | $263.10 Million | $24.23 Million | 0.092x | +190.78% |
| 2023-12-31 | $313.63 Million | $-31.81 Million | -0.101x | -188.42% |
| 2022-12-31 | $439.95 Million | $50.46 Million | 0.115x | -55.39% |
| 2021-12-31 | $433.11 Million | $111.36 Million | 0.257x | +281.78% |
| 2020-12-31 | $366.31 Million | $24.67 Million | 0.067x | -68.67% |
| 2019-12-31 | $194.98 Million | $41.91 Million | 0.215x | +439.16% |
| 2018-12-31 | $131.28 Million | $-8.32 Million | -0.063x | -102.79% |
| 2017-12-31 | $-29.15 Million | $-66.14 Million | 2.269x | -78.02% |
| 2016-12-31 | $-5.93 Million | $-61.17 Million | 10.321x | +1214.73% |
| 2015-12-31 | $63.47 Million | $-58.76 Million | -0.926x | +17.68% |
| 2014-12-31 | $54.57 Million | $-61.38 Million | -1.125x | -172.10% |
| 2013-12-31 | $115.54 Million | $-47.76 Million | -0.413x | -230.97% |
| 2012-12-31 | $-106.05 Million | $-33.47 Million | 0.316x | +4.43% |
| 2011-12-31 | $-71.29 Million | $-21.55 Million | 0.302x | -- |
About Tandem Diabetes Care Inc
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and … Read more